Journal articles
Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?
Abstract : Background
France is the European country with the lowest level of confidence in vaccines. Measurement of patients’ acceptability towards a future therapeutic HIV vaccine is critically important. Thus, the aim of this study was to evaluate patients’ acceptability of a future therapeutic HIV vaccine in a representative cohort of French patients living with HIV-AIDS (PLWHs).
Methods
This multicentre study used quantitative and qualitative methods to assess PLWHs’ opinions and their potential acceptance of a future therapeutic HIV vaccine. Cross-sectional study on 220 HIV-1 infected outpatients, aged 18–75 years.
Results
The participants’ characteristics were similar to those of the overall French PLWH population. Responses from the questionnaires showed high indices of acceptance: the mean score for acceptability on the Visual Analog Scale VAS was 8.4 of 10, and 92% of patients agreed to be vaccinated if a therapeutic vaccine became available. Acceptability depended on the expected characteristics of the vaccine, notably the duration of its effectiveness: 44% of participants expected it to be effective for life. This acceptance was not associated with socio-demographic, clinical (mode of contamination, duration of disease), quality of life, or illness-perception parameters. Acceptability was also strongly correlated with confidence in the treating physician.
Conclusion
The PLWHs within our cohort had high indices of acceptance to a future therapeutic HIV vaccine.
Cited literature [39 references]
https://hal-amu.archives-ouvertes.fr/hal-02263740
Contributor : Isabelle Combe <>
Submitted on : Friday, May 22, 2020 - 9:38:33 AM
Last modification on : Friday, October 23, 2020 - 4:35:08 PM
Contributor : Isabelle Combe <>
Submitted on : Friday, May 22, 2020 - 9:38:33 AM
Last modification on : Friday, October 23, 2020 - 4:35:08 PM
File
s12879-019-4056-6.pdf
Publication funded by an institution
Licence
Distributed under a Creative Commons Attribution 4.0 International License